Aprecia Pharms Drug Patent Portfolio
Aprecia Pharms owns 1 orange book drug protected by 5 US patents Given below is the list of Aprecia Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11160786 | Rapid disperse dosage form | 14 Mar, 2034 | Active |
| US9339489 | Rapid disperse dosage form containing levetiracetam | 14 Mar, 2034 | Active |
| US9669009 | Rapid disperse dosage form containing levetiracetam | 14 Mar, 2034 | Active |
| US6471992 | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same | 20 Feb, 2018 | Expired |
| US9463160 | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same | 20 Feb, 2018 | Expired |
Latest Legal Activities on Aprecia Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Aprecia Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Post Issue Communication - Certificate of Correction | 26 Jan, 2022 | US11160786 |
|
Recordation of Patent Grant Mailed
Critical
| 02 Nov, 2021 | US11160786 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 02 Nov, 2021 | US11160786 |
|
Email Notification
Critical
| 14 Oct, 2021 | US11160786 |
|
Issue Notification Mailed
Critical
| 13 Oct, 2021 | US11160786 |
| Dispatch to FDC | 01 Oct, 2021 | US11160786 |
|
Application Is Considered Ready for Issue
Critical
| 01 Oct, 2021 | US11160786 |
|
Issue Fee Payment Verified
Critical
| 28 Sep, 2021 | US11160786 |
|
Issue Fee Payment Received
Critical
| 28 Sep, 2021 | US11160786 |
|
Email Notification
Critical
| 01 Sep, 2021 | US11160786 |
|
Mail Notice of Allowance
Critical
| 01 Sep, 2021 | US11160786 |
|
Electronic Review
Critical
| 01 Sep, 2021 | US11160786 |
|
Notice of Allowance Data Verification Completed
Critical
| 30 Aug, 2021 | US11160786 |
| Interview Summary - Examiner Initiated - Telephonic | 26 Aug, 2021 | US11160786 |
| Appeal Brief Review Complete | 07 Jun, 2021 | US11160786 |
Aprecia Pharms's Family Patents
Aprecia Pharms drugs have patent protection in a total of 9 countries. It's US patent count contributes only to 34.8% of its total global patent coverage. Click
below to unlock the full patent family tree.
Aprecia Pharms Drug List
Given below is the complete list of Aprecia Pharms's drugs and the patents protecting them.
1. Spritam
Spritam is protected by 5 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11160786 | Rapid disperse dosage form |
14 Mar, 2034
(9 years from now)
| Active |
| US9339489 | Rapid disperse dosage form containing levetiracetam |
14 Mar, 2034
(9 years from now)
| Active |
| US9669009 | Rapid disperse dosage form containing levetiracetam |
14 Mar, 2034
(9 years from now)
| Active |
| US6471992 | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
20 Feb, 2018
(6 years ago)
| Expired |
| US9463160 | Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same |
20 Feb, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Spritam's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List